PatientsVille.com Logo

Rhinitis allergic and Stahist

PatientsVille

Rhinitis Allergic Symptoms and Causes

Each spring, summer, and fall, trees, weeds, and grasses release tiny pollen grains into the air. Some of the pollen ends up in your nose and throat. This can trigger a type of allergy called hay fever.

Symptoms can include

  • Sneezing, often with a runny or clogged nose
  • Coughing and postnasal drip
  • Itching eyes, nose and throat
  • Red and watery eyes
  • Dark circles under the eyes

Your health care provider may diagnose hay fever based on a physical exam and your symptoms. Sometimes skin or blood tests are used. Taking medicines and using nasal sprays can relieve symptoms. You can also rinse out your nose, but be sure to use distilled or sterilized water with saline. Allergy shots can help make you less sensitive to pollen and provide long-term relief.

NIH: National Institute of Allergy and Infectious Diseases

Check out the latest treatments for rhinitis allergic

rhinitis allergic treatment research studies

Stahist clinical trials, surveys and public health registries


Find Drug Side Effect reports



Stahist Side Effects

Vitreous Detachment (2)
Pleural Effusion (1)
Dry Eye (1)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

Recent Reviews

My father is 68 and retired, he is also diabetic. He suffers from severe joints, hip and back pain. He has been using panadol extra strength but finds it takes too long to act. He is also allergic to aspirin and was hospitalized with a ruptured u

I have ulcerative colitis, I have had 9 treatments of Remicade and have decided to stop. I have a lympnode in my neck that is enlarged now, I am so so tierd all the time, I have nausea all the time and now get more allergic reactions to things. M

I took Vitalux and I noticed that my eyes were getting blurry, watery and very itchy. I have allergies to ragweed and think that as there is marigold flowers in the ingredients this has been the reason that I have allergic conjunctivitis in both e

if montolucast suits pt how long can be given for allergic rhinitis and can it be repeated in next season

<strong>Well, the first night I turned beat red, itchy, etc. Second night the same thing happened but only after I had taken the aspirin...I WAS ALLERGIC TO ASPIRIN! So the third nightI took a 200 mg Ibuprofen wait

After about 3 yrs of Lasix (20mg) I developed an unknown allergic reaction that caused blistering on my hands and feet. My feet would get 20-30 at a time and my hands would get hundreds at a time. I had to take medication to keep the breakouts minimi

After several years of taking chondrosulf, two pills per day, I began having an allergic reaction every day and then stopped taking the pills. Is there a substitute that has the good effect on cartilege but without this reaction?? Many thanks, Bob

After taking asterpro for acouple weeks it began to make it hard for me to urinate i quit taking it to see if it helps it was really great for my allergic rhunitis that part of me felt better than it had in years i guess i cant use it anymore.

After taking the medication for two weeks I experience a severe allergic reaction to the medication. My side effects were paranoia hallucinations, anxiety, delusions, and psychosis. Due to the medication I was diagnosed bipolar.

Allergic reaction of sudden swelling of eyes, reddishness of eye, heavy sneezing.

Rhinitis Allergic Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Unknown  Posterior Vitreous Detachment (PVD) Assessment During Dual Retinal Vein Occlusion (RVO) Lucentis Evaluations
Conditions: Retinal Vein Occlusion;   Posterior Vitreous Detachment
Intervention: Drug: Ranibizumab
Outcome Measures: Mean change in BCVA at 6 months in the PVD positive and PVD negative ranibizumab-treated groups.;   To measure the mean change in central retinal thickness per OCT from baseline to Month 6 in PVD (+) and PVD (-) patients.;   To measure the mean change in leakage as determined by FA from baseline to Month 6 in PVD (+) and PVD (-) patients.
2 Recruiting Effect of Vitrectomy and Posterior Vitreous Detachment on Intravitreal Ranibizumab Pharmacokinetics
Condition: Age Related Macular Degeneration
Intervention: Drug: Ranibizumab
Outcome Measure: Ranibizumab half-life
3 Recruiting Clear Vision Study
Conditions: Posterior Vitreous Detachment;   Vitreous Floaters
Interventions: Procedure: Laser Ablation of Floaters;   Procedure: Sham Laser Treatment
Outcome Measures: Efficacy of the laser treatment measured by the improvement of visual acuity and floater specific Visual Function Questionnaire (VFQ).;   Number of complications in the laser treated eyes compared to the non-treated eyes
4 Not yet recruiting Vitreopapillary Traction and Optic Disc Morphology
Conditions: Posterior Vitreous Detachment;   Vitreomacular Traction;   Glaucoma;   Vitreopapillary Traction
Intervention: Other: OCT imaging/HRT imaging
Outcome Measures: Prevalence of VPT in glaucoma patients;   Change in VPT following trabeculectomy;   Change in VPT following ocriplasmin;   Proportion of patients with VPT that present with optic nerve head hemorrhage;   Proportion of patients with focal visual field defect that have corresponding focal VPT
5 Unknown  Intravitreal Ranibizumab in Exudative Age-related Macular Degeneration With Posterior Vitreomacular Adhesion
Condition: Neovascular Age-related Macular Degeneration
Intervention: Procedure: Intravitreal expansile gas and ranibizumab injection
Outcome Measures: Changes from baseline in visual acuity and central macular thickness at 12 months;   Number of participants with nonocular complications;   Number of participants with ocular complications
6 Unknown  A Safety and Efficacy Study of Vitreosolve® for Non-Proliferative Diabetic Retinopathy Subjects
Condition: Diabetic Retinopathy
Intervention: Drug: Vitreosolve
Outcome Measures: Ultrasound, OCT, and clinical exam;   Ultrasound ,OCT ,Safety, and Clinical Exam
7 Recruiting Prevalence of Vitreomacular Adhesion in Patients 40 Years and Older
Condition: Vitreomacular Adhesion
Intervention:
Outcome Measures: What is the overall prevalence of Vitreomacular adhesion in the population 40 years and older?;   Is there is a significant correlation between VMA and various maculopathies including diabetic macular edema, retinal vascular occlusion, and age-related macular degeneration?
8 Unknown  Comparison of Two Techniques for Epiretinal or Internal Limiting Membrane Peel
Conditions: Epiretinal Membrane;   Vitreomacular Traction
Interventions: Procedure: using ILM forceps alone;   Procedure: Breaking and peeling with end-grasping forceps
Outcome Measures: Change in visual acuity;   Change in humphrey visual field
9 Unknown  Triple Therapy for Diffuse Diabetic Macular Edema
Condition: Diffuse Diabetic Macular Edema
Intervention: Procedure: Triple therapy for diffuse diabetic macular edema
Outcome Measures: Best-corrected visual acuity (BCVA) and central macular thickness (CMT);   Presence of vitreomacular traction or epimacular membrane, grade of DR, patients age, HbA1c level, BMI, systemic hypertension
10 Recruiting Flexibility, Efficacy, and Safety of a Foldable Capsular Vitreous Body in the Treatment of Severe Retinal Detachment
Condition: Retinal Detachment
Intervention: Device: foldable capsular vitreous body(FCVB)
Outcome Measures: Complete retinal reattach rate at the 52 weeks after implantation of the FCVB;   Retinal reattach rate, Visual function,and Silicone oil change
11 Recruiting Pre-Operative Intravitreal Bevacizumab for Tractional Retinal Detachment Secondary to Proliferative Diabetic Retinopathy
Condition: Tractional Retinal Detachment Secondary to Proliferative Diabetic Retinopathy
Interventions: Drug: Intravitreal bevacizumab;   Procedure: Small-gauge pars plana vitrectomy
Outcome Measures: Intraoperative bleeding;   Total surgical time;   Post-operative vitreous hemorrhage;   Visual acuity change;   Number of endodiathermy applications;   Intraoperative breaks;   Change in central macular thickness;   Proportion of eyes gaining at least 15 letters of BCVA
12 Not yet recruiting Analysis of Aqueous and Vitreous Humor
Conditions: Proliferative Diabetic Retinopathy;   Macular Degeneration;   Macular Hole;   Neovascular Glaucoma
Intervention: Drug: Ranibizumab
Outcome Measures: Cytokine Levels;   Serum Pharmacokinetics
13 Unknown  Triple Treatment for Detachment of Retinal Pigment Epithelium Secondary to Polypoidal Choroidal Vasculopathy
Conditions: Choroidal Neovascularization;   Retinal Pigment Epithelial Detachment
Intervention: Other: Triple Therapy
Outcome Measures: Auxiliary Exams - Optical Coherency Tomography (OCT);   Auxiliary Exams - Indocyanine green angiography (ICGA);   Auxiliary Exams - Fluorescein Angiography (FA)
14 Recruiting Double Endotamponade With Perfluorodecalin and Silicone Oil in Retinal Detachment Surgery.
Condition: Retinal Detachment
Intervention: Procedure: Vitrectomy and tamponade
Outcome Measures: Retinal reattachment rate;   Percentage of patients with best corrected visual acuity >/= 20.200
15 Not yet recruiting Corneal Endothelial Cell Loss After Pneumatic Retinopexy for the Repair of Primary Rhegmatogenous Retinal Detachment
Condition: Rhegmatogenous Retinal Detachment
Interventions: Procedure: Pneumatic retinopexy;   Procedure: vitrectomy;   Drug: sulfur hexafluoride (SF6);   Device: 5/8-in 25-gauge needle;   Device: laser
Outcome Measure: Endothelial cells count as measured by specular microscopy
16 Unknown  Intravitreal Bevacizumab for Management of Active Progressive Proliferative Diabetic Retinopathy (PDR)
Condition: Diabetic Retinopathy
Intervention: Drug: bevacizumab
Outcome Measures: Regression of diabetic retinopathy;   visual acuity;   neovascularization;   fibrous proliferation;   traction retinal detachment;   vitreous hemorrhage;   pan retinal photocoagulation
17 Recruiting Intravitreal Gas for Vitreomacular Adhesion
Condition: Vitreomacular Adhesion
Intervention: Procedure: Intravitreal Injection of sulfahexafluoride gas
Outcome Measures: Proportion of patients with resolution of vitreomacular adhesion at Day 28;   Change in Visual Acuity;   Time to resolution of vitreomacular adhesion;   Proportion of patients requiring vitrectomy surgery;   Incidence of Retinal Tears and Retinal Detachment
18 Unknown  Preoperative Injection of Bevacizumab Prior to Vitreoretinal Surgery in Diabetic Tractional Retinal Detachment
Conditions: Intravitreal Bevacizumab Injection;   Pars Plana Vitrectomy;   Tractional Retinal Detachment;   Diabetic Retinopathy
Intervention: Drug: Bevacizumab
Outcome Measures: Best corrected visual acuity;   Anatomic status of the retina
19 Unknown  Comparison High-Density Silicone Oils in Retinal Detachment
Condition: Retinal Detachment
Interventions: Drug: Oxane HD [oil-RMN3-mixture];   Drug: Densiron [(F6H8)
Outcome Measures: visual acuity;   anatomical results;   complication: hypotony,;   vitreous hemorrhage,;   inflammatory reaction,;   cataract,;   chronic hypotony,;   IOP elevated intraocular pressure,;   pseudohypopyon,;   fibrin,;   emulsification droplets in the anterior chamber
20 Not yet recruiting Bevacizumab Against Recurrent Retinal Detachment
Conditions: Retinal Detachment;   Proliferative Vitreoretinopathy
Intervention: Drug: Bevacizumab
Outcome Measures: Complete success of primary vitrectomy surgery;   Presence of proliferative vitreoretinopathy